EurekaMag.com logo
+ Site Statistics
References:
53,869,633
Abstracts:
29,686,251
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

The impact of treatment non-compliance on mortality in people with type 1 diabetes



The impact of treatment non-compliance on mortality in people with type 1 diabetes



Journal of Diabetes and Its Complications 27(3): 219-223



To determine if a diagnostic record of poor treatment compliance (medication non-compliance and/or non-attendance at medical appointments) was associated with all-cause mortality in people with type 1 diabetes. This is an observational cohort study of data extracted from The Health Improvement Network (THIN) database, comprising data on patients served by over 350 primary care practices in the UK. Participants were included in the study if they had diagnostic codes indicative of type 1 diabetes. Treatment non-compliance was defined as missing one or more scheduled appointment, or one or more codes indicating medication non-compliance. Of 2946 patients with type 1 diabetes, 867 (29.4%) had a record of either appointment non-attendance or medication non-compliance in the 30month compliance assessment period. The crude, unadjusted mortality rate for those patients who were treatment non-compliant was 1.462 (95% CI 0.954 2.205). Following adjustment for confounding factors, treatment non-compliance was associated with increased all-cause mortality (HR=1.642; 95% CI 1.055 2.554). Treatment non-compliance was associated with increased all-cause mortality in patients with type 1 diabetes. Understanding and addressing factors that contribute to patient treatment non-compliance will be important in improving the life expectancy of patients with type 1 diabetes.

(PDF emailed within 0-6 h: $19.90)

Accession: 036697909

Download citation: RISBibTeXText

PMID: 23157988

DOI: 10.1016/j.jdiacomp.2012.10.006



Related references

The impact of treatment noncompliance on mortality in people with type 2 diabetes. Diabetes Care 35(6): 1279-1284, 2012

Mortality after incident cancer in people with and without type 2 diabetes: impact of metformin on survival. Diabetes Care 35(2): 299-304, 2012

Compliance to treatment and type 2 diabetes: impact on glycemic balance. Presse Medicale 32(2): 70-70, 2003

All-cause and cardiovascular mortality in middle-aged people with type 2 diabetes compared with people without diabetes in a large U.K. primary care database. Diabetes Care 36(8): 2366-2371, 2014

Early Detection and Treatment of Type 2 Diabetes Reduce Cardiovascular Morbidity and Mortality: A Simulation of the Results of the Anglo-Danish-Dutch Study of Intensive Treatment in People With Screen-Detected Diabetes in Primary Care (ADDITION-Europe). Diabetes Care 38(8): 1449-1455, 2016

Short-term impact of HbA1c on morbidity and all-cause mortality in people with type 2 diabetes: a Danish population-based observational study. Diabetologia 55(9): 2361-2370, 2012

Economic impact of compliance to treatment with antidiabetes medication in type 2 diabetes mellitus: a review paper. Journal of Medical Economics 13(1): 8-15, 2011

The Bypass Angioplasty Revascularization Investigation 2 Diabetes randomized trial of different treatment strategies in type 2 diabetes mellitus with stable ischemic heart disease: impact of treatment strategy on cardiac mortality and myocardial infarction. Circulation 120(25): 2529-2540, 2010

Mortality trends among people with type 1 and type 2 diabetes in Australia: 1997-2010. Diabetes Care 2014;37:2579-2586. Diabetes Care 38(4): 733-734, 2015

Impact on mortality and incidence of end-stage renal disease of education and treatment at a diabetes center among patients with type 1 diabetes: comparison of two subgroups in the Japanese DERI cohort. Journal of Diabetes and Its Complications 18(3): 155-159, 2004

Quality of life as a key indicator of patient satisfaction and treatment compliance in people with type 2 diabetes mellitus in the IMPROVE study: a multicentre, open label, non-randomised, observational trial. Journal of the Indian Medical Association 107(7): 464-470, 2010

Cultivation of microalgae Chlorella zofingiensis on municipal wastewater and biogas slurry towards bioenergy. Journal of Bioscience and Bioengineering, 2018

Potential positive impact of group-based diabetes dialogue meetings on diabetes distress and glucose control in people with type 1 diabetes. Patient Education and Counseling 99(12): 1978-1983, 2016

Can people with type 2 diabetes live longer than those without? A comparison of mortality in people initiated with metformin or sulphonylurea monotherapy and matched, non-diabetic controls. Diabetes, Obesity & Metabolism 16(11): 1165-1173, 2015

C-peptide concentration, mortality and vascular complications in people with Type 2 diabetes. The Skaraborg Diabetes Register. Diabetic Medicine 32(1): 85-89, 2015